Liver damage arrests growth mediated by the somatotroph axis, which prevents liver cell death and inflammation, but increases fibrosis in nonalcoholic fatty liver disease (NAFLD). The explanation for this effect could lie in the relationship between the activating transcription factor 3 (ATF-3) and insulin-like growth factor 1 (IGF-1), according to a study from the University of California at Berkeley.
TOTUM-448 is a unique combination of plant extracts designed to reduce hepatic steatosis, a risk factor for nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.
Modern molecular techniques have progressed to the point where sequencing can seem almost quaint. At the Basic Science Symposium of the American Association for the Study of Liver Diseases 2022 meeting (AASLD 2022), new techniques were on full display, with sessions devoted to epigenetics, microbiome analysis and spatial transcriptomics. But the first session was still on genetic variants in all their forms – rare variants, common variants and nongermline mutations.
Modern molecular techniques have progressed to the point where sequencing can seem almost quaint. At the Basic Science Symposium of The Liver Meeting 2022, new techniques were on full display, with sessions devoted to epigenetics, microbiome analysis and spatial transcriptomics. But the first session was still on genetic variants in all their forms – rare variants, common variants and non-germline mutations.
Inipharm Inc. has divulged thiazoles/isothiazoles acting as 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13) inhibitors reported to be useful for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, cirrhosis, alcoholic liver disease, drug-induced liver injury and portal hypertension.
Peking University researchers in collaboration with the NIH have discovered a new biochemical pathway related to a bacterium that eliminates nicotine in the intestine. The findings could lead to new ways to improve nonalcoholic fatty liver disease in smokers.
Peking University researchers in collaboration with the NIH have discovered a new biochemical pathway related to a bacterium that eliminates nicotine in the intestine. The findings could lead to new ways to improve nonalcoholic fatty liver disease in smokers.
Peking University researchers in collaboration with the NIH have discovered a new biochemical pathway related to a bacterium that eliminates nicotine in the intestine. The findings could lead to new ways to improve nonalcoholic fatty liver disease (NAFLD) in smokers. In addition to the lung and the brain, nicotine can accumulate in the intestine, where the bacteria Bacteroides xylanisolvens could reduce its concentration and the severity of NAFLD. In their study, published in Nature Oct. 19, 2022, the researchers described the enzymes involved in this process and a new undiscovered pathway.
Altimmune Inc. has come under scrutiny from investors after weight loss data from a phase Ib trial of its nonalcoholic fatty liver disease drug, pemvidutide, sent its shares on a roller coaster ride.
Research led by the University of Texas Southwestern Medical Center reveals a protein signature that can reliably predict whether patients with nonalcoholic fatty liver disease (NAFLD) are likely to develop hepatocellular carcinoma, the most common form of liver cancer.
